Recommendations for Self-Report Outcome Measures in Vulvodynia Clinical Trials

Caroline F. Pukall, Sophie Bergeron, Candace Brown, Gloria Bachmann, Ursula Wesselmann

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Objectives: Vulvodynia (idiopathic chronic vulvar pain) is a prevalent condition associated with significant and negative impacts in many areas of function. Despite the increased research interest in vulvodynia in recent years, recommendations for outcome measures for use in clinical trials are missing. The purpose of this paper, therefore, was to provide recommendations for outcome measures for vulvodynia clinical trials so that consistent measures are used across trials to facilitate between-study comparisons and the conduct of large multicenter trials, and to improve measurement of the multiple dimensions of vulvodynia. Methods: Given that provoked vestibulodynia (PVD) - characterized by provoked pain localized to the vaginal opening - is the most common subtype of vulvodynia and the current main focus of clinical trials, this paper focused on recommended outcome measures in PVD clinical trials. The framework used to guide the selection of outcome measures was based on the one proposed by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT). Results: The IMMPACT framework provided a well-suited guideline for outcome measure recommendations in PVD clinical trials. However, given the provoked presentation of PVD and the significant impact it has on sexuality, modifications to some of the IMMPACT recommendations were made and specific additional measures were suggested. Discussion: Measures that are specific to vulvovaginal pain are ideal for adoption in PVD clinical trials, and many such measures currently exist that allow the relevant IMMPACT domains to be captured.

Original languageEnglish (US)
Pages (from-to)756-765
Number of pages10
JournalClinical Journal of Pain
Volume33
Issue number8
DOIs
StatePublished - Jan 1 2017

Fingerprint

Vulvodynia
Self Report
Outcome Assessment (Health Care)
Clinical Trials
Pain Measurement
Pain
Sexuality
Chronic Pain
Multicenter Studies

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Recommendations for Self-Report Outcome Measures in Vulvodynia Clinical Trials. / Pukall, Caroline F.; Bergeron, Sophie; Brown, Candace; Bachmann, Gloria; Wesselmann, Ursula.

In: Clinical Journal of Pain, Vol. 33, No. 8, 01.01.2017, p. 756-765.

Research output: Contribution to journalReview article

Pukall, Caroline F. ; Bergeron, Sophie ; Brown, Candace ; Bachmann, Gloria ; Wesselmann, Ursula. / Recommendations for Self-Report Outcome Measures in Vulvodynia Clinical Trials. In: Clinical Journal of Pain. 2017 ; Vol. 33, No. 8. pp. 756-765.
@article{df153dff9ce04804afed5cd5f573c959,
title = "Recommendations for Self-Report Outcome Measures in Vulvodynia Clinical Trials",
abstract = "Objectives: Vulvodynia (idiopathic chronic vulvar pain) is a prevalent condition associated with significant and negative impacts in many areas of function. Despite the increased research interest in vulvodynia in recent years, recommendations for outcome measures for use in clinical trials are missing. The purpose of this paper, therefore, was to provide recommendations for outcome measures for vulvodynia clinical trials so that consistent measures are used across trials to facilitate between-study comparisons and the conduct of large multicenter trials, and to improve measurement of the multiple dimensions of vulvodynia. Methods: Given that provoked vestibulodynia (PVD) - characterized by provoked pain localized to the vaginal opening - is the most common subtype of vulvodynia and the current main focus of clinical trials, this paper focused on recommended outcome measures in PVD clinical trials. The framework used to guide the selection of outcome measures was based on the one proposed by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT). Results: The IMMPACT framework provided a well-suited guideline for outcome measure recommendations in PVD clinical trials. However, given the provoked presentation of PVD and the significant impact it has on sexuality, modifications to some of the IMMPACT recommendations were made and specific additional measures were suggested. Discussion: Measures that are specific to vulvovaginal pain are ideal for adoption in PVD clinical trials, and many such measures currently exist that allow the relevant IMMPACT domains to be captured.",
author = "Pukall, {Caroline F.} and Sophie Bergeron and Candace Brown and Gloria Bachmann and Ursula Wesselmann",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/AJP.0000000000000453",
language = "English (US)",
volume = "33",
pages = "756--765",
journal = "Clinical Journal of Pain",
issn = "0749-8047",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Recommendations for Self-Report Outcome Measures in Vulvodynia Clinical Trials

AU - Pukall, Caroline F.

AU - Bergeron, Sophie

AU - Brown, Candace

AU - Bachmann, Gloria

AU - Wesselmann, Ursula

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objectives: Vulvodynia (idiopathic chronic vulvar pain) is a prevalent condition associated with significant and negative impacts in many areas of function. Despite the increased research interest in vulvodynia in recent years, recommendations for outcome measures for use in clinical trials are missing. The purpose of this paper, therefore, was to provide recommendations for outcome measures for vulvodynia clinical trials so that consistent measures are used across trials to facilitate between-study comparisons and the conduct of large multicenter trials, and to improve measurement of the multiple dimensions of vulvodynia. Methods: Given that provoked vestibulodynia (PVD) - characterized by provoked pain localized to the vaginal opening - is the most common subtype of vulvodynia and the current main focus of clinical trials, this paper focused on recommended outcome measures in PVD clinical trials. The framework used to guide the selection of outcome measures was based on the one proposed by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT). Results: The IMMPACT framework provided a well-suited guideline for outcome measure recommendations in PVD clinical trials. However, given the provoked presentation of PVD and the significant impact it has on sexuality, modifications to some of the IMMPACT recommendations were made and specific additional measures were suggested. Discussion: Measures that are specific to vulvovaginal pain are ideal for adoption in PVD clinical trials, and many such measures currently exist that allow the relevant IMMPACT domains to be captured.

AB - Objectives: Vulvodynia (idiopathic chronic vulvar pain) is a prevalent condition associated with significant and negative impacts in many areas of function. Despite the increased research interest in vulvodynia in recent years, recommendations for outcome measures for use in clinical trials are missing. The purpose of this paper, therefore, was to provide recommendations for outcome measures for vulvodynia clinical trials so that consistent measures are used across trials to facilitate between-study comparisons and the conduct of large multicenter trials, and to improve measurement of the multiple dimensions of vulvodynia. Methods: Given that provoked vestibulodynia (PVD) - characterized by provoked pain localized to the vaginal opening - is the most common subtype of vulvodynia and the current main focus of clinical trials, this paper focused on recommended outcome measures in PVD clinical trials. The framework used to guide the selection of outcome measures was based on the one proposed by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT). Results: The IMMPACT framework provided a well-suited guideline for outcome measure recommendations in PVD clinical trials. However, given the provoked presentation of PVD and the significant impact it has on sexuality, modifications to some of the IMMPACT recommendations were made and specific additional measures were suggested. Discussion: Measures that are specific to vulvovaginal pain are ideal for adoption in PVD clinical trials, and many such measures currently exist that allow the relevant IMMPACT domains to be captured.

UR - http://www.scopus.com/inward/record.url?scp=84995390422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995390422&partnerID=8YFLogxK

U2 - 10.1097/AJP.0000000000000453

DO - 10.1097/AJP.0000000000000453

M3 - Review article

C2 - 27841834

AN - SCOPUS:84995390422

VL - 33

SP - 756

EP - 765

JO - Clinical Journal of Pain

JF - Clinical Journal of Pain

SN - 0749-8047

IS - 8

ER -